Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   39211   clinical trials with a EudraCT protocol, of which   6426   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-005645-20
    Sponsor's Protocol Code Number:A3921082
    National Competent Authority:Denmark - DHMA
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2013-06-25
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedDenmark - DHMA
    A.2EudraCT number2012-005645-20
    A.3Full title of the trial
    A PHASE 2B, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY, SAFETY, LOCAL TOLERABILITY AND PHARMACOKINETICS OF 2 DOSE STRENGTHS AND 2 REGIMENS OF TOFACITINIB OINTMENT IN SUBJECTS WITH CHRONIC PLAQUE PSORIASIS
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study to test efficacy, tolerability, safety and pharmacokinetics of Tofacitinib ointment in subjects with mild, moderate or severe chronic plaque psoriasis.
    A.4.1Sponsor's protocol code numberA3921082
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPfizer Inc. 235 East 42nd Street, New York, 10017
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportPfizer Inc
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPfizer Inc
    B.5.2Functional name of contact pointClinical Trials.gov Call Center
    B.5.3 Address:
    B.5.3.1Street AddressEast 42nd Street
    B.5.3.2Town/ cityNew York
    B.5.3.3Post codeNY 10017
    B.5.3.4CountryUnited States
    B.5.4Telephone number0018007181021
    B.5.5Fax number0013037391119
    B.5.6E-mailClinicaltrials.gov_inquiries@pfizer.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nametofacitinib
    D.3.2Product code CP-690,550-00
    D.3.4Pharmaceutical form Ointment
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPCutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTOFACITINIB
    D.3.9.1CAS number 477600-75-2
    D.3.9.2Current sponsor codeCP-690,550-00
    D.3.9.4EV Substance CodeSUB33104
    D.3.10 Strength
    D.3.10.1Concentration unit mg/g milligram(s)/gram
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nametofacitinib
    D.3.2Product code CP-690,550-00
    D.3.4Pharmaceutical form Ointment
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPCutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTOFACITINIB
    D.3.9.1CAS number 477600-75-2
    D.3.9.2Current sponsor codeCP-690,550-00
    D.3.9.4EV Substance CodeSUB33104
    D.3.10 Strength
    D.3.10.1Concentration unit mg/g milligram(s)/gram
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboOintment
    D.8.4Route of administration of the placeboCutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic Plaque Psoriasis
    E.1.1.1Medical condition in easily understood language
    A chronic, recurrent skin condition of variable severity.
    E.1.1.2Therapeutic area Diseases [C] - Skin and Connective Tissue Diseases [C17]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.0
    E.1.2Level LLT
    E.1.2Classification code 10071117
    E.1.2Term Plaque psoriasis
    E.1.2System Organ Class 100000004858
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    1. To characterize the efficacy of tofacitinib ointment (10 mg/g and 20 mg/g) applied once daily (QD) or twice daily (BID) over 12 weeks in subjects with mild or moderate chronic plaque psoriasis compared to the corresponding placebo ointment (vehicle) (QD or BID).
    2. To characterize safety of tofacitinib ointment (10 mg/g and 20 mg/g) applied QD or BID over 12 weeks in subjects with mild or moderate chronic plaque psoriasis.
    3. To characterize local tolerability of tofacitinib ointment (10 mg/g and 20 mg/g) applied QD or BID over 12 weeks in subjects with mild or moderate chronic plaque psoriasis.
    E.2.2Secondary objectives of the trial
    Characterize effects on patient reported outcome (PRO) measures of tofacitinib ointment (10 mg/g and 20 mg/g) applied QD or BID over 12 weeks of treatment in subjects with mild or moderate chronic plaque psoriasis.

    -Determine the pharmacokinetics (PK) of tofacitinib when applied as an ointment (10 mg/g and 20 mg/g) QD or BID over 12 weeks in subjects with chronic plaque psoriasis.
    -Characterize efficacy by baseline severity of psoriasis tofacitinib ointment (10 mg/g and 20 mg/g) applied QD or BID over 12 weeks of treatment in subjects with mild, moderate, or severe chronic plaque psoriasis.
    -Characterize efficacy by body region of tofacitinib ointment (10 mg/g and 20 mg/g) applied QD or BID over 12 weeks of treatment in subjects with mild or moderate chronic plaque psoriasis.
    -Characterize local tolerability by body region of tofacitinib ointment (10 mg/g and 20 mg/g) applied QD or BID over 12 weeks of treatment in subjects with mild or moderate chronic plaque psoriasis.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
    2. Subjects who are willing and able to comply with scheduled visits, treatment plan, study drug application to all treatment eligible plaques, laboratory tests, and other study procedures.
    3. Be at least 18 years of age at time of informed consent.
    4. Have had a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Visit 1 (Baseline/Day 1).
    5. Have a PGA-C score of 2 (mild), 3 (moderate) or 4 (severe) at Visit 1 (Baseline/Day 1).
    6. At Visit 1 (Baseline/Day 1), have plaque psoriasis covering 2% to 20% of total body surface area (BSA) on the trunk and limbs (excluding palms, soles, and nails) with at least 1% BSA involvement on the trunk or limbs excluding palms, soles, elbows, knees and below the knee areas. Plaque psoriasis of the scalp, palms or soles, and nail psoriasis will not be included in the total BSA with psoriasis to determine eligibility.
    7. Female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28 days after the last dose of assigned treatment. A subject is of childbearing potential if, in the opinion of the investigator, she is biologically capable of having children and is sexually active.
    8. Must agree to avoid prolonged exposure to the sun and avoid use of tanning booths, sun lamps or other ultraviolet light sources during the study.
    9. If receiving concomitant medications for any reason, must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to Visit 1 (Baseline/Day 1). Subject must be willing to stay on a stable regimen.
    10. No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB) as defined by the following:
    a. A negative QuantiFERON-TB Gold (QFT-G) In-Tube test or negative Mantoux/Purified Protein Derivative (PPD) tuberculin skin test performed at or within the 3 months prior to Screening. A positive QuantiFERON-TB Gold (QFT-G) In-Tube test or positive Mantoux/Purified Protein Derivative (PPD) tuberculin skin test is exclusionary. It is recommended that subjects with a history of Bacille Calmette Guérin (BCG) vaccination be tested with the QFT-G test since the Mantoux/PPD tuberculin skin test may be positive due to vaccination. See Section 7.4.5 for requirements for Mantoux/PPD tuberculin skin testing. A QFT-G or Mantoux/PPD tuberculin skin test is not required if the subject has previously received a documented adequate course of therapy for either latent or active TB infection or is currently receiving a documented adequate treatment for latent TB infection;
    b. No history of either untreated or inadequately treated latent or active TB infection;
    c. If a subject has previously received an adequate course of therapy for either latent(9 months of isoniazid in a locale where rates of primary multi-drug TB resistance are <5% or an acceptable alternative regimen) or active (acceptable multi-drug regimen) TB infection, neither a QFT-G test nor a Mantoux/PPD tuberculin skin test is needed, but a chest radiograph(s) (per local standard/guidelines) must be obtained if not performed within 3 months prior to a given Screening visit.
    Documentation of adequate treatment for TB and negative chest radiograph(s) results must be obtained prior to Visit 1 (Baseline/Day 1). If the current incidence rates of multi-drug resistant TB infection in the locale are unavailable, an adequate treatment regimen should be defined as the regimen recommended by the health ministry or expert panel in the locale;
    d. A subject who is currently being treated for active TB infection is to be excluded;
    e. A subject who is currently being treated for latent TB infection can only be enrolled with confirmation of current incidence rates of multi-drug resistant TB infection in the locale, documentation of an adequate treatment regimen, and with prior approval by the Pfizer Medical Monitor (or designee). If the current incidence rates of multi-drug resistant TB infection in the locale are unavailable, an adequate treatment regimen should be defined as the regimen recommended by the health ministry or expert panel in the locale.

    For inclusion condition 11 please refer to the protocol.
    E.4Principal exclusion criteria
    1. Currently have non-plaque forms of psoriasis, (eg, erythrodermic, guttate, or pustularpsoriasis, keratoderma blennorrhagicum [Reiter’s syndrome]) with the exception of nail psoriasis which is allowed. Psoriasis of palms and soles is allowed only if considered to be part of the generalized plaque psoriasis. Subjects with other forms of palmo-plantar psoriasis (eg, palmo-plantar involvement as part of keratoderma blennorrhagicum, pustular psoriasis of the palms and soles, or pustular psoriasis of the digits) are to be excluded.
    2. Have current drug-induced psoriasis, eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs, or lithium.
    3. Have evidence of skin conditions (eg, eczema, fungal infection) at the time of Visit 1 (Baseline/Day 1) that would interfere with evaluation of psoriasis.
    4. If planned initiation of, or changes to, concomitant medication that could affect psoriasis (eg, beta blockers, calcium channel blockers, antimalarial drugs, or lithium) are to occur within 2 weeks prior to Visit 1 (Baseline/Day 1) and/or during the study.
    5. The following laboratory values at the Wash-out or Screening visit:
    a. Hemoglobin <10.0 g/dL or hematocrit <30%
    b. White blood cell count <3.0 x 10 9 /L (<3000/mm3)
    c. Absolute neutrophil count of <1.5 x 10 9 /L (<1500/mm3)
    d. Absolute lymphocyte count of <0.5 x 10 9 /L (<500/mm3)
    e. Platelet count <100 x 10 9 /L (<100,000/mm3)
    f. Estimated Creatinine Clearance <40 mL/min based on the Cockcroft-Gault calculation (Appendix 1) or serum creatinine >1.5 times the upper limit of normal (ULN)
    g. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values >2 times the ULN
    h. Any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the subject’s participation in the study.
    6. Pregnant females, breastfeeding females, or females of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception (per Section 4.4.5.1) for at least 28 days after last dose of investigational product.
    7. Have current or recent history of clinically significant severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, psychiatric or neurological disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator or Pfizer (or designee), the subject is inappropriate for entry into this study, or unwilling/unable to comply with study procedures and life style guidelines.
    8. Have a history of any lymphoproliferative disorder (such as Epstein Barr Virus [EBV] related lymphoproliferative disorder), history of lymphoma, leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.
    9. Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster.
    10. Have a history of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Visit 1 (Baseline/Day 1).
    11. Have a history of infection requiring oral or topical antimicrobial therapy within 2 weeks prior to Visit 1 (Baseline/Day 1).
    12. Have been vaccinated with live or attenuated live vaccine within the 6 weeks prior to Visit 1 (Baseline/Day 1), or expects to be vaccinated with these vaccines during treatment or during the 6 weeks following the last dose of study drug.
    13. Have had any prior treatment with non B cell-specific lymphocyte depleting agents/therapies (eg, alemtuzumab [CamPath], alkylating agents [eg, cyclophosphamide or chlorambucil], total lymphoid irradiation, etc) or have received rituximab or other selective B-lymphocyte depleting agents (including experimental agents).
    14. Have previously participated in any study of oral or topical tofacitinib (tofacitinib, CP-690,550, formerly known as tasocitinib), unless confirmed to have been randomized to and treated with placebo or placebo topical formulation (vehicle) only.
    15. Have a history of alcohol or substance abuse, unless in full remission for greater than 6 months prior to Visit 1 (Baseline/Day 1).
    16. A Screening 12-lead ECG that demonstrates clinically significant abnormalities requiring urgent treatment (eg, acute myocardial infarction, serious tachy- or bradyarrhythmias) or that are indicative of serious underlying heart disease (eg, cardiomyopathy, major congenital heart disease, low voltage in all leads).

    For exclusion conditions 17 - 24 please refer to the protocol.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoints will be analyzed for subjects with mild or moderate psoriasis as defined by the baseline Calculated Physician's Global Assessment (PGA-C) score and include the proportion of subjects achieving a PGA-C response of “clear” (0) or “almost clear” (1) and ≥2 grade/point improvement from baseline at Week 8, and the proportion of subjects achieving a PGA-C response of “clear” (0) or “almost clear” (1) and 2 ≥ grade/point improvement from baseline at Week 12.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 8 and Week 12
    E.5.2Secondary end point(s)
    The secondary efficacy endpoints (measured at Week 8 and at Week 12 separately) include the proportion of subjects achieving a PGA-C response of “clear” (0) or “almost clear” (1); the proportion of subjects achieving a Gestalt Physician's Global Assessment (PGA-G) response of “clear” (0) or “almost clear” (1) and ≥2 grade/point improvement from baseline; the percent change from baseline in Psoriasis Area and Severity Index (PASI); Psoriasis Area and Severity Index 75 (PASI75) response, ie, the proportion of subjects achieving at least a 75% reduction in PASI relative to baseline; and the percent change from baseline in Body Surface Area (BSA) affected with psoriasis.

    Safety Endpoints: Safety endpoints include incidence of treatment-emergent adverse events (AE) and specific clinical laboratory abnormalities.

    Local Tolerability Endpoints: These include percent of subjects discontinued due to application site adverse events, and incidence of local tolerability AEs.

    PK Endpoints: PK analyses include tofacitinib PK concentration for pre-dose samples (all subjects) and post-dose samples (subjects of selected sites).
    E.5.2.1Timepoint(s) of evaluation of this end point
    Efficacy Endpoint: Week 8 and Week 12.
    Safety and local tolerability endpoint: All 12 weeks of the treatment period.
    PK endpoints: Week 2, Week 4, Week 8 and Week 12.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Patient reported outcomes
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial6
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA16
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Denmark
    Germany
    Poland
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of Trial in all participating countries is defined as Last Subject Last Visit which is the last follow up visit for the last subject.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months11
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 430
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 50
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state18
    F.4.2 For a multinational trial
    F.4.2.2In the whole clinical trial 480
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    No special measures; subjects may be treated as per standard local practice outside the scope of the clinical trial
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-06-25
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-05-23
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2014-09-16
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA